{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"41.0","upperLimit":"66.3","value":"53.8"},{"groupId":"OG001","lowerLimit":"54.9","upperLimit":"78.8","value":"67.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"65"}],"units":"Participants"}],"description":"Retention is defined as the percentage of participants who complete the 12 week visit","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants receive memantine hydrochloride PO BID) on days 1-81 in the absence of unacceptable toxicity.\n\nmemantine hydrochloride: Estimate participation, accrual, adherence, and retention of cancer survivors who smoke and are randomized to receive memantine (10 mg twice daily) or a matching placebo for 12 weeks.","id":"OG000","title":"Arm I - Memantine"},{"description":"Participants receive a placebo PO BID on days 1-81 in the absence of unacceptable toxicity.\n\nplacebo: Placebo by mouth through completion of 12 weeks.","id":"OG001","title":"Arm II - Placebo"}],"paramType":"NUMBER","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"12 weeks","title":"Retention","type":"PRIMARY","unitOfMeasure":"percentage of participants"}